Market Cap ₹766 Cr.
Stock P/E 56.7
P/B 3
Current Price ₹352
Book Value ₹ 118.3
Face Value 10
52W High ₹479
Dividend Yield 0%
52W Low ₹ 230.1
Sakar Healthcare ltd. is an totally India-based organisation, which is engaged within the production of pharmaceutical products. The Company is engaged in presenting Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Liquid Injectables in ampoules and vials, and Dry Powder Injections. It additionally affords Lyophilized Injectables. It operates as contract manufacturer for pharmaceutical MNC. The Company's products include Albendazole oral suspension USP, Cetirizine hydrochloride syrup, Cefadroxil and potassium clavulanate capsules, Cefixime and potassium clavulanate capsules, Cefpodoxime proxetil Capsule, Cefalexin oral suspension BP, Cefixime for oral suspension, Cefuroxime Axetil drugs BP, Adrenallin tartrate Injection, Quinine dihydrochloride Injection, Vitamin B-complicated Injection, Chloroquine phosphate Injection, Tranexamic Acid Injection, Palonosetron hydrochloride Injection and others. The Company has its presence in about 40 international locations.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 32 | 30 | 37 | 29 | 31 | 33 | 41 | 39 | 34 | 37 |
| Other Income | 1 | 0 | 1 | 0 | 1 | 2 | 2 | 2 | 1 | 0 |
| Total Income | 32 | 30 | 37 | 29 | 31 | 35 | 42 | 41 | 35 | 37 |
| Total Expenditure | 25 | 23 | 27 | 21 | 22 | 25 | 33 | 30 | 25 | 28 |
| Operating Profit | 8 | 7 | 10 | 8 | 9 | 11 | 10 | 11 | 10 | 9 |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 4 | 4 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 |
| Profit Before Tax | 5 | 3 | 6 | 4 | 4 | 5 | 4 | 4 | 4 | 3 |
| Provision for Tax | 3 | 3 | -3 | 1 | 2 | 1 | -0 | 1 | 1 | 1 |
| Profit After Tax | 2 | 0 | 9 | 3 | 2 | 4 | 4 | 3 | 4 | 2 |
| Adjustments | 0 | 0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 |
| Profit After Adjustments | 2 | 0 | 9 | 3 | 2 | 4 | 4 | 3 | 4 | 2 |
| Adjusted Earnings Per Share | 1.4 | 0.1 | 5.2 | 1.7 | 1 | 2.2 | 2.1 | 1.5 | 1.7 | 1 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|
| Net Sales | 83 | 95 | 128 | 133 | 151 |
| Other Income | 2 | 1 | 2 | 5 | 5 |
| Total Income | 85 | 96 | 130 | 138 | 155 |
| Total Expenditure | 63 | 72 | 99 | 100 | 116 |
| Operating Profit | 22 | 24 | 32 | 38 | 40 |
| Interest | 2 | 2 | 3 | 6 | 8 |
| Depreciation | 7 | 8 | 10 | 15 | 17 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -0 | 0 |
| Profit Before Tax | 12 | 13 | 19 | 17 | 15 |
| Provision for Tax | 3 | 3 | 4 | 4 | 3 |
| Profit After Tax | 10 | 11 | 15 | 13 | 13 |
| Adjustments | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 10 | 11 | 15 | 13 | 13 |
| Adjusted Earnings Per Share | 6.4 | 6.8 | 8.9 | 6.7 | 6.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 4% | 17% | 0% | 0% |
| Operating Profit CAGR | 19% | 20% | 0% | 0% |
| PAT CAGR | -13% | 9% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 36% | 34% | 42% | NA% |
| ROE Average | 8% | 11% | 11% | 11% |
| ROCE Average | 9% | 11% | 12% | 12% |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|
| Shareholder's Funds | 81 | 98 | 127 | 173 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 12 | 38 | 85 | 98 |
| Other Non-Current Liabilities | 7 | 8 | 9 | 10 |
| Total Current Liabilities | 14 | 33 | 47 | 54 |
| Total Liabilities | 115 | 178 | 268 | 336 |
| Fixed Assets | 66 | 69 | 205 | 267 |
| Other Non-Current Assets | 28 | 75 | 13 | 14 |
| Total Current Assets | 22 | 34 | 50 | 56 |
| Total Assets | 115 | 178 | 268 | 336 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | 19 | 15 | 36 | 33 |
| Cash Flow from Investing Activities | -22 | -47 | -90 | -74 |
| Cash Flow from Financing Activities | 3 | 32 | 55 | 41 |
| Net Cash Inflow / Outflow | -0 | -0 | -0 | 0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 |
| # | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 6.43 | 6.84 | 8.87 | 6.7 |
| CEPS(Rs) | 11.16 | 12 | 14.52 | 14.57 |
| DPS(Rs) | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 54.35 | 63.04 | 74.45 | 91.04 |
| Core EBITDA Margin(%) | 23.56 | 23.87 | 22.88 | 24.95 |
| EBIT Margin(%) | 17.46 | 16.6 | 17.03 | 17.21 |
| Pre Tax Margin(%) | 14.73 | 13.97 | 14.76 | 12.74 |
| PAT Margin (%) | 11.6 | 11.28 | 11.84 | 9.57 |
| Cash Profit Margin (%) | 20.13 | 19.78 | 19.38 | 20.8 |
| ROA(%) | 8.36 | 7.3 | 6.81 | 4.22 |
| ROE(%) | 11.83 | 11.88 | 13.44 | 8.48 |
| ROCE(%) | 14.79 | 13.16 | 12.09 | 8.95 |
| Receivable days | 36.22 | 39.7 | 37.8 | 49.62 |
| Inventory Days | 48.09 | 51.3 | 42.53 | 40.48 |
| Payable days | 46.13 | 90.05 | 123.3 | 140.43 |
| PER(x) | 7.77 | 16.54 | 15.24 | 29.94 |
| Price/Book(x) | 0.92 | 1.79 | 1.82 | 2.2 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.1 | 2.31 | 2.53 | 3.76 |
| EV/Core EBITDA(x) | 4.22 | 9.21 | 10.29 | 13.2 |
| Net Sales Growth(%) | 0 | 14.17 | 35.35 | 4 |
| EBIT Growth(%) | 0 | 8.57 | 38.88 | 5.09 |
| PAT Growth(%) | 0 | 11.01 | 42.1 | -15.95 |
| EPS Growth(%) | 0 | 6.34 | 29.65 | -24.44 |
| Debt/Equity(x) | 0.2 | 0.43 | 0.73 | 0.69 |
| Current Ratio(x) | 1.52 | 1.01 | 1.07 | 1.03 |
| Quick Ratio(x) | 0.75 | 0.54 | 0.77 | 0.74 |
| Interest Cover(x) | 6.41 | 6.3 | 7.51 | 3.85 |
| Total Debt/Mcap(x) | 0.22 | 0.24 | 0.4 | 0.31 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 67.54 | 67.54 | 67.54 | 62.1 | 62.1 | 60.72 | 60.72 | 54.15 | 53.15 | 53.15 |
| FII | 8.76 | 8.76 | 8.76 | 16.12 | 16.12 | 15.74 | 15.74 | 14.03 | 13.76 | 13.52 |
| DII | 0 | 0 | 0 | 0.55 | 0.33 | 0 | 0 | 10.82 | 10.62 | 10.62 |
| Public | 23.7 | 23.7 | 23.7 | 21.24 | 21.45 | 23.54 | 23.54 | 21 | 22.47 | 22.71 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.16 | 1.16 | 1.16 | 1.16 | 1.16 | 1.16 | 1.16 | 1.16 | 1.16 | 1.16 |
| FII | 0.15 | 0.15 | 0.15 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.29 |
| DII | 0 | 0 | 0 | 0.01 | 0.01 | 0 | 0 | 0.23 | 0.23 | 0.23 |
| Public | 0.41 | 0.41 | 0.41 | 0.4 | 0.4 | 0.45 | 0.45 | 0.45 | 0.49 | 0.49 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.71 | 1.71 | 1.71 | 1.86 | 1.86 | 1.9 | 1.9 | 2.13 | 2.17 | 2.17 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
